'Health-related quality of life in patients with advanced well-differentiated pancreatic and extra pancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double- blind, phase III trials (SANET-p and SANET-ep)' (vol 169, pg 1, 2022)-MedSci.cn

'Health-related quality of life in patients with advanced well-differentiated pancreatic and extra pancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double- blind, phase III trials (SANET-p and SANET-ep)' (vol 169, pg 1, 2022)

Li, JR; Cheng, YJ; Bai, CM; Xu, JM; Shen, L; Li, J; Zhou, ZW; Li, ZP; Chi, YHBL; Yu, XJ; Li, EX; Xu, N; Liu, TS; Lou, WH; Bai, YX; Yuan, XL; Wang, XW; Yuan, Y; Chen, J; Guan, S; Fan, SH; Su, WG

Bai, CM (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Med Oncol, Beijing, Peoples R China.;Xu, JM (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Dept Gastrointestinal Oncol, Beijing, Peoples R China.;Shen, L (通讯作者)，Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China.

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

'Health-related quality of life in patients with advanced well-differentiated pancreatic and extra pancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double- blind, phase III trials (SANET-p and SANET-ep)' (vol 169, pg 1, 2022)

科室

工具

服务